Back

Select your region

Corporate

Europe:

Flag Albania Albania Flag Bosnia and Herzegovina Bosnia and Herzegovina Flag Bulgaria Bulgaria Flag Croatia Croatia Flag Cyprus Cyprus Flag Montenegro Montenegro Flag Czech Republic Czech Republic Flag Denmark Denmark Flag Estonia Estonia Flag Spain Spain Flag Kosovo Kosovo Flag Lithuania Lithuania Flag Latvia Latvia Flag Luxembourg Luxembourg Flag Macedonia Macedonia Flag Germany Germany Flag Poland Poland Flag Portugal Portugal Flag Romania Romania Flag Serbia Serbia Flag Slovakia Slovakia Flag Slovenia Slovenia Flag Switzerland Switzerland Flag Sweden Sweden Flag Turkey Turkey Flag Hungary Hungary Flag United Kingdom United Kingdom Flag Italy Italy

Asia:

Flag UAE UAE Flag Hong Kong Hong Kong Flag Kuwait Kuwait Flag Lebanon Lebanon

Africa:

Flag South Africa South Africa

Arrange a consultation about stem cells

Learn more

Get in touch with us today!

Would you like to find out more about our services? Fill out the form below and we will contact you as soon as possible to provide you with all the necessary information and answer your questions.

    We would like to point out that the personal data provided in the form will be processed by FamiCord Suisse, based in Switzerland (BusinessPark Zug Sumpfstrasse 26, 6302 Zug), for the purpose of contacting you by telephone in connection with the provision of service information.

    Image

    List of life saving
    transplantations

    List of uses for stem cells approved by the FamiCord Group’s laboratories:

    Image
    List of uses for stem cells approved by the FamiCord Group’s laboratories:
    Nr. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
    401 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Canada 26
    402 Apheresis Allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 40
    403 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Netherlands 68
    404 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy United Kingdom 56
    405 Apheresis Allogeneic Myelodysplastic/Myeloproliferative Neoplasms Hematology 2026 Standard Therapy Spain 65
    406 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 63
    407 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 58
    408 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 44
    409 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Czechia 61
    410 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Australia 54
    411 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Poland 11
    412 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2026 Standard Therapy USA 64
    413 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 64
    414 Apheresis autologous Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 32
    415 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    416 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Germany 54
    417 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 64
    418 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 72
    419 Apheresis autologous Peripheral T-cell Lymphoma Hematology 2026 Standard Therapy Germany 56
    420 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    421 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    422 Apheresis autologous Anaplastic Large-Cell Lymphoma Hematology 2026 Standard Therapy Germany 47
    423 Apheresis autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 60
    424 Apheresis allogeneic Vexas-Syndrome with UBA1-Mutation Hematology 2026 Standard Therapy Germany 67
    425 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 27
    426 Apheresis allogeneic Primary Myelofibrosis PMF Hematology 2026 Standard Therapy Poland 57
    427 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 48
    428 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Switzerland 67
    429 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 42
    430 Apheresis allogeneic MPS-I: Hurler Syndrome Hematology 2026 Standard Therapy Russia 1
    431 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 29
    432 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy USA 47
    433 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 66
    434 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 4
    435 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 68
    436 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 63
    437 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Lithuania 40
    438 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy Germany 68
    439 Apheresis allogeneic Chronic Lymphocytic Leukemia Hematology 2026 Standard Therapy Netherlands 61
    440 Apheresis allogeneic Acute Lymphoblastic leukemia Hematology 2026 Standard Therapy Germany 21
    441 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 72
    442 Apheresis allogeneic Non-Hodgkin Lymphoma Hematology 2026 Standard Therapy USA 36
    443 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Germany 57
    444 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Belgium 63
    445 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy United Kingdom 54
    446 Apheresis allogeneic Other Malignancy, Specify Hematology 2026 Standard Therapy USA 54
    447 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 76
    448 Apheresis allogeneic Myelodysplastic Disorders Hematology 2026 Standard Therapy France 73
    449 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 75
    450 Apheresis allogeneic Hodgkin Lymphoma Hematology 2026 Standard Therapy Poland 47
    451 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy USA 68
    452 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Italy 40
    453 Apheresis allogeneic Acute Myeloid Leukemia Hematology 2026 Standard Therapy Macedonia 59
    454 Apheresis allogeneic Combined Immunodeficiency Hematology 2026 Standard Therapy Belgium 4
    455 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Australia 13
    456 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 33
    457 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Italy 38
    458 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Russian Federation 28
    459 Apheresis allogeneic Severe Aplastic Anemia Hematology 2026 Standard Therapy Germany 58
    460 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Austria 54
    461 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 74
    462 Apheresis allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy United Kingdom 20
    463 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 57
    464 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 69
    465 Apheresis allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 64
    466 Apheresis allogeneic Myelodysplastic Syndrome Hematology 2026 Standard Therapy Germany 56
    467 Apheresis autologous Myeloma Hematology 2026 Standard Therapy Portugal 42
    468 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    469 Apheresis Autologous T-Cell Lymphoma Hematology 2026 Standard Therapy Germany 68
    470 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 71
    471 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    472 Apheresis Allogeneic T-Cell Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Germany 24
    473 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 67
    474 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 62
    475 Apheresis Autologous Plasma Cell Leukemia Hematology 2026 Standard Therapy Germany 43
    476 Apheresis Autologous Mantle Cell Lymphoma Hematology 2026 Standard Therapy Germany 60
    477 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    478 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 68
    479 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 70
    480 Apheresis Allogeneic Primary Myelopathic Polycythemia Hematology 2026 Standard Therapy Germany 67
    481 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 61
    482 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 56
    483 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Germany 69
    484 Apheresis Autologous Multiple Myeloma Hematology 2026 Standard Therapy Portugal 32
    485 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    486 Apheresis Autologous Lymphoma Hematology 2026 Standard Therapy Portugal 64
    487 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 42
    488 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 65
    489 Apheresis Allogeneic Chronic myelomonocytic leukemia Hematology 2026 Standard Therapy Germany 73
    490 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Spain 63
    491 Apheresis Allogeneic Thalassemia Major Hematology 2026 Standard Therapy Italy 6
    492 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy USA 63
    493 Apheresis Allogeneic Hemophagocytic Lymphohistiocytosis Hematology 2026 Standard Therapy India 3
    494 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Bulgaria 32
    495 Apheresis Allogeneic Mixed-Phenotype Acute Leukemia Hematology 2026 Standard Therapy Poland 40
    496 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2026 Standard Therapy USA 64
    497 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2026 Standard Therapy Ukraine 58
    498 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy Poland 62
    499 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2026 Standard Therapy France 45
    500 Apheresis Allogeneic T-cell non-Hodgkin Lymphoma (Mycosis Fungoides) Hematology 2026 Standard Therapy Portugal 43